Hepatitis/MASH

Prime Therapeutics reports more than 94% of patients who completed at last 8 weeks of treatment with Harvoni were cleared of HCV.

An adverse effect with interferon-ribavirin Hepatitis C therapy that does not stop after discontinuation.

Baby Boomer age group testing levels for hepatitis C virus remained very low.

Top news of the day from across the health care landscape.

Need for an increase in HCV testing awareness among health care providers and baby boomers.

Physicians should test for more common liver conditions rather than rare diseases.

Top news of the day from across the health care landscape.

Manufacturers say they are unable to lower the cost of some drugs due to pharmacy benefit manager involvement.

Gilead feuds with Express Scripts over hepatitis C virus drug costs.

Up to 30% of people who have HIV, and more than 80% of HIV-positive injection drug users also have hepatitis C virus (HCV) as well.

Cannabidiol found in cannabis could be used as a novel treatment for hepatitis C virus

Cannabidiol was overserved to elicit antiviral properties against HCV.

The Iowa Department of Public Health released its first report on hepatitis C virus.

Flawed patents challenged on blockbuster HCV drugs to allow generic production.

Assay quantitates HCV viral load and confirms active HCV infection.

Research indicates hepatitis C virus is linked to cancers other than hepatocellular carcinoma and non-Hodgkin lymphoma.

New findings suggest that hepatitis C may cause cancers other than hepatocellular carcinoma and non-Hodgkin lymphoma.

Top articles of the week on Specialty Pharmacy Times.

Glecaprevir/pribrentasvir well-tolerated in patients with HCV genotype 1.

For patients with HIV, liver disease is a major cause of morbidity and mortality.

Proposals such as allowing Medicare price negotiation, capping out-of-pocket drug costs, importing drugs, and limiting manufacturer’ spending on patient marketing could all result in lower HCV drug costs.

The prevalence of cirrhosis has increased by nearly 40% in patients with HCV.

With the entrance of more effective and less costly drugs, older treatments will likely decrease.

HCV rates 3 times higher in patients with lupus.

The FDA has accepted AbbVie’s New Drug Application (NDA) for and granted priority review to its investigational, pan-genotype regimen of glecaprevir/pibrentasvir (G/P).